February 27, 2015

Latest At The Meeting series focuses on applied PRRS research & ARC

Audio series highlights historical comparisons to PRV & large-scale PRRS study

The latest At The Meeting (ATM) audio program on swine health from The Morrison Group covers new developments in the management of porcine reproductive and respiratory syndrome (PRRS) presented during the recent North American PRRS Symposium held in Chicago, IL, December, 2014. The ATM program, which features disease, research and practical swine health information from leading veterinary experts, is available for the benefit of swine veterinarians and producers.

This newest PRRS management ATM program is divided into three 15-minute segments with moderator Bob Morrison, DVM, Ph.D., discussing different PRRS-related topics. In the first of the three audio segments, Dr. Morrison talks with John Kolb, DVM, Boehringer Ingelheim Vetmedica, Inc., about results of a study involving three large scale, system based breeding herds totaling 124,000 sows and respective pig flows. In these large systems, the use of Ingelvac PRRS® MLV vaccine in pigs, replacement gilts and breeding herds, along with herd closure, resulted in significant improvement in PRRS stability and a subsequent impact on pig performance that is documented, repeatable and cost-effective. 

In the second of the three PRRS At The Meeting segments, Tim Loula, DVM, Swine Vet Center, St. Peter, MN, discusses how area regional control programs are helping producers in a region improve the stability of their swine herds and reducing the impact of PRRS.

In the third segment of the PRRS ATM program, Joe Conner, DVM, M.S., with Carthage Veterinary Services, Carthage, IL, provides a historical comparison of pseudorabies control and eradication programs and the lessons learned that can be applied to PRRSV control and elimination.

This free audio program is sponsored by BIVI as a service to the swine industry and is ideal for veterinarians and producers to listen to while driving or working around the farm. It is available on CD and can easily be downloaded at from swinecast.com. Previous At The Meeting programs on timely disease management topics also are available at swinecast.com.

About Boehringer Ingelheim

Boehringer Ingelheim Vetmedica, Inc., (BIVI) is a leader in the animal health industry with its portfolio of innovative vaccine and pharmaceutical solutions for the prevention and treatment of disease within the swine, cattle, equine and pet markets. BIVI is the U.S. division of the global Boehringer Ingelheim Animal Health GmbH. Our U.S. headquarters are located within the KC Animal Health Corridor in St. Joseph, Mo., with other sites in Ames, Fort Dodge and Sioux Center, Iowa.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates and more than 47,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim’s culture. Involvement in social projects, caring for the employees and their families and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors of all Boehringer Ingelheim’s endeavors.

With nearly 3,000 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about $1.46 billion (1.07 billion euros) in 2013. In our research-driven Animal Health business, Boehringer Ingelheim continually invests more than 10% of net sales of the Animal Health business in R&D.

Media Contact

Rene Ward

Director, U.S. Animal Health Communications
3902 Gene Field Road
St. Joseph, Missouri 64506